Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib with Bevacizumab or Dietary Intervention in Advanced Ovarian Cancer
NCT06954584Phase 3Recruiting
- Sponsor
- Tongji Hospital
- Start
- May 2025
- Primary completion
- May 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fluzoparib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Tongji Hospital. Started May 2025; status: recruiting.
02
Drugs
fluzoparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT06954584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06954584.